{
    "clinical_study": {
        "@rank": "90845", 
        "arm_group": [
            {
                "arm_group_label": "Treatment Order A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment Order B", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment Order C", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment Order D", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This open-label, randomized, single-dose, 4-sequence, 4-period cross-over study will compare\n      the bioequivalence of 3 test formulations to a reference formulation of alectinib\n      (RO5424802) in healthy adult volunteers. All participants will receive each of the 4\n      treatments in a randomized sequence. Each treatment will be given as a single oral\n      administration after an overnight fast, followed by a 10-day washout period. Total time on\n      study is expected to last up to 75 days."
        }, 
        "brief_title": "A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib in Healthy Volunteers", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 to 55 years of age inclusive\n\n          -  Body mass index (BMI) between 18 to 32 kg/m2 inclusive\n\n          -  Healthy, male and female non-smoking subjects and former smoking subjects\n\n          -  Male subjects and their partners of childbearing potential must be willing to use\n             effective contraception as defined by the protocol\n\n          -  Willing to abstain from xanthine-containing beverages and food (coffee, tea, cola,\n             chocolate, and \"energy drinks\") use through the study\n\n          -  Willing to abstain from grapefruit, pomelo, star fruit or Seville orange containing\n             products from day 7 prior study start until study end\n\n          -  Willing to avoid prolonged sun exposure throughout study\n\n        Exclusion Criteria:\n\n          -  Women of child-bearing potential, pregnant of breast-feeding woman, men with partners\n             who are pregnant of breast-feeding\n\n          -  Clinically significant abnormalities on physical examination, vital signs, or\n             laboratory test results during screening or prior to admission to the study unit\n\n          -  Positive test for drugs of abuse, alcohol or cotinine test at screening or prior to\n             admission to the study unit or suspicion of regular consumption of drug(s) of abuse\n\n          -  History of recent alcohol consumption exceeding 2 standard drinks per day on average.\n             Alcohol consuming is prohibited from 72 hours prior to study start until the end of\n             the study\n\n          -  Subjects with any risk factors of family history for QT/QTcF prolongation or ECG\n             abnormalities\n\n          -  A history of any concurrent clinically significant hematologic, renal, hepatic,\n             pulmonary, neurological, psychiatric, allergies, gastrointestinal, metabolic or\n             endocrine disorder, or cardiovascular disease or infections\n\n          -  Use of any medications (prescriptions or over-the-counter), within 2 weeks or 5\n             half-lives (whichever is longer) before the first dose of study medication with\n             exception of acetaminophen up to 2 g per day up to 48 hours prior to dosing, not to\n             exceed 4 g total during the week prior to dosing\n\n          -  Routine or chronic use of more than 2 g of acetaminophen daily\n\n          -  Use of any herbal supplements  (e.g.,  St. John's Wort) or any metabolic inducers\n             within 4 weeks or 5 half-lives (whichever is longer) before the first dose of study\n             medication, including but not limited to the following drugs: rifampin, rifabutin,\n             glucocorticoids, carbamazepine, phenytoin, and phenobarbital\n\n          -  Strenuous activity, sunbathing or contact sports are not allowed from 4 days prior to\n             study start until the end of the study\n\n          -  Participation in an investigational drug or device study within 45 days or 5\n             half-lives (whichever time period is longer), or 6 months for biologic therapies,\n             prior to first dosing\n\n          -  Donation of blood over 450 mL within 45 days prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "49", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074553", 
            "org_study_id": "NP29040"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment Order A", 
                    "Treatment Order B", 
                    "Treatment Order C", 
                    "Treatment Order D"
                ], 
                "description": "Single dose will be given after an overnight fast.", 
                "intervention_name": "alectinib, Reference formulation", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment Order A", 
                    "Treatment Order B", 
                    "Treatment Order C", 
                    "Treatment Order D"
                ], 
                "description": "Single dose will be given after an overnight fast.", 
                "intervention_name": "alectinib, test formulation 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment Order A", 
                    "Treatment Order B", 
                    "Treatment Order C", 
                    "Treatment Order D"
                ], 
                "description": "Single dose will be given after an overnight fast.", 
                "intervention_name": "alectinib, test formulation 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment Order A", 
                    "Treatment Order B", 
                    "Treatment Order C", 
                    "Treatment Order D"
                ], 
                "description": "Single dose will be given after an overnight fast.", 
                "intervention_name": "alectinib, test formulation 3", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78744"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A RANDOMIZED, OPEN-LABEL, SINGLE DOSE, CROSS-OVER STUDY TO INVESTIGATE THE BIOEQUIVALENCE OF THREE RO5424802 TEST FORMULATIONS VERSUS A REFERENCE FORMULATION FOLLOWING ORAL ADMINISTRATION IN HEALTHY SUBJECTS", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Bioequivalence as assessed by area under the curve (AUC) comparisons", 
            "safety_issue": "No", 
            "time_frame": "Up to 75 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074553"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: maximum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 75 days"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Up to 75 days"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}